Medical Device
Argenx Prepares FDA Filing to Expand Vyvgart Use in Myasthenia Gravis After Late-Stage Trial Win
Argenx; Vyvgart; FDA approval; myasthenia gravis; prefilled syringe; self-injection; chronic inflammatory demyelinating polyneuropathy; generalized myasthenia gravis; clinical trial
Teva Execs Shrug Off Pharmaceutical Tariff Threat as Turnaround Strategy Rolls Forward
Teva; tariff threat; pharmaceutical tariffs; turnaround strategy; supply chain; pivot to growth; earnings; innovative medicines; Richard Francis; operating profit margin
Tourmaline Bio’s Heart Drug Pacibekitug Shows Promise Against Cardiovascular Inflammation, Targets Competition with Novo, CSL
Tourmaline Bio; heart drug; pacibekitug; cardiovascular inflammation; inflammation markers; Novo Nordisk; CSL; Phase 2 trial; FDA; IL-6
Leqembi’s Expansion and Blood Test Impact: Analyst Sees Gradual Uptake Boost
Leqembi; Eisai; Biogen; Alzheimer’s disease; FDA approval; blood test; launch; maintenance dosing; autoinjector; subcutaneous; market adoption
Argenx brews up DTC push for Vyvgart Hytrulo prefilled syringe in generalized myasthenia gravis
Vyvgart Hytrulo, prefilled syringe, FDA approval, self-administration, generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), DTC campaign, patient empowerment
Teva plots thousands of job cuts as restructuring drive enters ‘acceleration’ phase
Workforce reduction (8%), $700 million cost savings, Strategic overhaul, Generics to biopharmaceuticals pivot, Operational streamlining, R&D investment
FDA lifts clinical hold on Atara’s Epstein-Barr T-cell programme
United States Food and Drug Administration, Study on Hold, Atara, Hoist device, Atara ‘s, EBVALLO
HR25: LifeSignals launches cardiac monitoring patch to compete with iRhythm, Philips
Preventive monitoring, Plaque (lesion), Philips, Heart, iRhythm, LifeSignals, Medical Devices
Former FDA Officials Sound Alarm: Visible Changes May Be Tip of the Iceberg
United States Food and Drug Administration, public health medicine (field), Changing, Vaccines, Leadership, Policy, drug safety, Previous, KAT5 wt Allele, Icebergs, Disease Outbreaks, Alarm device, Visible
Third Harmonic Bio to Liquidate, Selling Key Urticaria Drug Asset THB335
Third Harmonic Bio liquidation , THB335 drug sale , chronic spontaneous urticaria (CSU) , KIT inhibitor , biopharma exit strategy , clinical-stage biotech , shareholder value maximization